Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

NCT02198794 is registered in ClinicalTrials.gov with Auspex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02198794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02198794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Lead sponsor
Auspex Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 20, 2014
Completion date
December 14, 2020
Enrollment
343 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

tardive dyskinesia